Cargando…

Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in (68)GaPSMA-11 PET images of patients with primary prostate cancer

INTRODUCTION: Primary prostate cancer (PCa) can be visualized on prostate-specific membrane antigen positron emission tomography (PSMA-PET) with high accuracy. However, intraprostatic lesions may be missed by visual PSMA-PET interpretation. In this work, we quantified and characterized the intrapros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zamboglou, Constantinos, Bettermann, Alisa S., Gratzke, Christian, Mix, Michael, Ruf, Juri, Kiefer, Selina, Jilg, Cordula A., Benndorf, Matthias, Spohn, Simon, Fassbender, Thomas F., Bronsert, Peter, Chen, Mengxia, Guo, Hongqian, Wang, Feng, Qiu, Xuefeng, Grosu, Anca-Ligia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113179/ https://www.ncbi.nlm.nih.gov/pubmed/33210239 http://dx.doi.org/10.1007/s00259-020-05111-3

Ejemplares similares

Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference
por: Zamboglou, Constantinos, et al.
Publicado: (2019)

Comparison of Manual and Semi-Automatic [(18)F]PSMA-1007 PET Based Contouring Techniques for Intraprostatic Tumor Delineation in Patients With Primary Prostate Cancer and Validation With Histopathology as Standard of Reference
por: Spohn, Simon K. B., et al.
Publicado: (2020)

Intraindividual comparison between (68)Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients
por: Spohn, Simon, et al.
Publicado: (2020)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

Isotropic Expansion of the Intraprostatic Gross Tumor Volume of Primary Prostate Cancer Patients Defined in MRI—A Correlation Study With Whole Mount Histopathological Information as Reference
por: Kramer, Maria, et al.
Publicado: (2020)

Intraindividual Comparison Between [(18)F] PSMA-1007 PET/CT and Multiparametric MRI for Radiotherapy Planning in Primary Prostate Cancer Patients
por: Marinescu, Ioana M., et al.
Publicado: (2022)

The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2021)

Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies
por: Spohn, Simon K.B., et al.
Publicado: (2021)

The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2018)

Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parameters
por: Marinescu, Ioana M., et al.
Publicado: (2022)

(68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison
por: Zamboglou, Constantinos, et al.
Publicado: (2016)

PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
por: Zamboglou, Constantinos, et al.
Publicado: (2021)

The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging
por: Eder, Ann-Christin, et al.
Publicado: (2021)

(99m)Tc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: proof of principle
por: Mix, Michael, et al.
Publicado: (2021)

Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With De Novo Lymph Node-Positive Prostate Cancer
por: Spohn, Simon K.B., et al.
Publicado: (2022)

Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
por: Arbuznikova, Daria, et al.
Publicado: (2023)

Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
por: Zamboglou, Constantinos, et al.
Publicado: (2018)

3 Tesla multiparametric MRI for GTV-definition of Dominant Intraprostatic Lesions in patients with Prostate Cancer – an interobserver variability study
por: Rischke, Hans Christian, et al.
Publicado: (2013)

Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml
por: Kumar, Niraj, et al.
Publicado: (2019)

Comparison of (68)Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology
por: Zamboglou, Constantinos, et al.
Publicado: (2017)

Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference
por: Spohn, Simon K. B., et al.
Publicado: (2021)

Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy
por: Spohn, Simon K. B., et al.
Publicado: (2023)

Results from extended lymphadenectomies with [(111)In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
por: Jilg, Cordula A., et al.
Publicado: (2020)

Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts
por: Goodman, Christopher D., et al.
Publicado: (2019)

Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour
por: Gaudreault, Mathieu, et al.
Publicado: (2022)

Individualized Decision Making in Transperineal Prostate Biopsy: Should All Men Undergo an Additional Systematic Biopsy?
por: Sigle, August, et al.
Publicado: (2022)

Evaluation of Dose-Painting in the Dominant Intraprostatic Lesions by Radiobiological Parameters using (68)Ga- PSMA PET/CT
por: Bamneshin, Khadijeh, et al.
Publicado: (2022)

The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis
por: Spohn, Simon K. B., et al.
Publicado: (2022)

Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients
por: Spohn, S. K. B., et al.
Publicado: (2022)

Determination of Intraprostatic and Intratesticular Androgens
por: Šimková, Markéta, et al.
Publicado: (2021)

Comparison of PET/CT and whole-mount histopathology sections of the human prostate: a new strategy for voxel-wise evaluation
por: Schiller, F., et al.
Publicado: (2017)

External validation of a convolutional neural network for the automatic segmentation of intraprostatic tumor lesions on (68)Ga-PSMA PET images
por: Ghezzo, Samuele, et al.
Publicado: (2023)

Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
por: Schmidt Hegemann, Nina-Sophie, et al.
Publicado: (2020)

Impact of multileaf collimator width on intraprostatic dose painting plans for dominant intraprostatic lesion of prostate cancer
por: Abe, Eisuke, et al.
Publicado: (2010)

Intraprostatic Hydatid Cyst: An Unusual Presentation
por: Nouira, Yassine, et al.
Publicado: (2006)

Evaluation of the Ginsburg Scheme: Where Is Significant Prostate Cancer Missed?
por: Sigle, August, et al.
Publicado: (2021)

Bone marrow impairment during early [(177)Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
por: Kind, Felix, et al.
Publicado: (2022)

(18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
por: Zhou, Shuoming, et al.
Publicado: (2022)

The Role of Intraprostatic Inflammation in the Acute Urinary Retention
por: Asgari, Seyed Alaeddin, et al.
Publicado: (2011)

Quantification of the margin required for treating intraprostatic lesions
por: Studenski, Matthew T., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0s9hfhcr6foqvcu2eb5m2r3ta7